Format

Send to

Choose Destination
Pediatr Blood Cancer. 2020 May;67(5):e28152. doi: 10.1002/pbc.28152. Epub 2020 Mar 8.

Impact of Medicaid expansion on access and healthcare among individuals with sickle cell disease.

Author information

1
Clinical Health Systems and Analytics Division, Duke University School of Nursing, Durham, North Carolina.
2
Sickle Cell Data Collection Program, Tracking California/Public Health Institute, Richmond, California.
3
Biological Sciences Division, University of Chicago, Chicago, Illinois.
4
Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
5
Center for Health Services and Outcomes Research, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
6
Veterans Affairs Health Services Research and Development Service, Chicago, Illinois.
7
Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
8
Division of Hematology, Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
9
Department of Hematology/Oncology, University of California San Francisco Benioff Children's Hospital, Oakland, Illinois.

Abstract

PURPOSE:

Sickle cell disease (SCD) is associated with high acute healthcare utilization. The purpose of this study was to examine whether Medicaid expansion in California increased Medicaid enrollment, increased hydroxyurea prescriptions filled, and decreased acute healthcare utilization in SCD.

METHODS:

Individuals with SCD (≤65 years and enrolled in Medicaid for ≥6 total calendar months any year between 2011 and 2016) were identified in a multisource database maintained by the California Sickle Cell Data Collection Program. We describe trends and changes in Medicaid enrollment, hydroxyurea prescriptions filled, and emergency department (ED) visits and hospital admissions before (2011-2013) and after (2014-2016) Medicaid expansion in California.

RESULTS:

The cohort included 3635 individuals. Enrollment was highest in 2014 and lowest in 2016 with a 2.8% annual decease postexpansion. Although <20% of the cohort had a hydroxyurea prescription filled, the percentage increased by 5.2% annually after 2014. The ED visit rate was highest in 2014 and decreased slightly in 2016, decreasing by 1.1% annually postexpansion. Hospital admission rates were similar during the pre- and postexpansion periods. Young adults and adults had higher ED and hospital admission rates than children and adolescents.

CONCLUSIONS:

Medicaid expansion does not appear to have improved enrollment or acute healthcare utilization among individuals with SCD in California. Future studies should explore whether individuals with SCD transitioned to other insurance plans or became uninsured postexpansion, the underlying reasons for low hydroxyurea utilization, and the lack of effect on hospital admissions despite a modest effect on ED visits.

KEYWORDS:

Medicaid expansion; health disparity; healthcare utilization; hydroxyurea; sickle cell disease

PMID:
32147964
PMCID:
PMC7096276
[Available on 2021-05-01]
DOI:
10.1002/pbc.28152

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center